Finding the Goldilocks zone in neoadjuvant radioimmunotherapy

Advances in cancer immunotherapy have led to clinical trials of immunotherapy-based neoadjuvant treatments for early stage non-small-cell lung cancer. Evidence for priming of the immune system using both preoperative short-course radiotherapy and immunotherapy in this setting has now emerged from a...

Full description

Saved in:
Bibliographic Details
Published in:Nature reviews. Clinical oncology 2021-09, Vol.18 (9), p.545-546
Main Authors: Schneiders, Famke L., Senan, Suresh
Format: Article
Language:English
Subjects:
692/4028/67/1059/2325
692/4028/67/1059/485
692/4028/67/1612/1350
Cancer immunotherapy
Care and treatment
Clinical trials
Humans
Immune system
Immunotherapy
Lung cancer
Lung cancer, Non-small cell
Medicine
Medicine & Public Health
Neoadjuvant Therapy
News & Views
news-and-views
Non-small cell lung carcinoma
Oncology
Radiation therapy
Radioimmunotherapy
Radiosurgery
Testing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Advances in cancer immunotherapy have led to clinical trials of immunotherapy-based neoadjuvant treatments for early stage non-small-cell lung cancer. Evidence for priming of the immune system using both preoperative short-course radiotherapy and immunotherapy in this setting has now emerged from a randomized phase II study incorporating pathological and immunological end points.
ISSN:1759-4774
1759-4782
DOI:10.1038/s41571-021-00540-x